Gerresheimer expects 350M Euro diabetes/diet drug revenue boost by 2026-27, driven by obesity drug demand.

German packaging and medical equipment firm, Gerresheimer, expects diabetes and diet drug sales to boost its annual revenue by 350 million euros by the 2026-27 financial year. The company's CFO, Bernd Metzner, shared this outlook following the release of the first-quarter results. Obesity drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, are administered using injector pens produced by Gerresheimer, contributing to the growth in revenue.

Articles

Financial Express

ForexTV

SaltWire Network

PR-inside

Street Insider

Yahoo

RTTNews

-- show less --

Further Reading

Related Stories